<DOC>
	<DOCNO>NCT00046787</DOCNO>
	<brief_summary>The purpose study determine whether OSI-211 ( Liposomal Lurtotecan ) effective safe treatment patient recurrent small cell lung cancer .</brief_summary>
	<brief_title>Efficacy Safety Study OSI-211 ( Liposomal Lurtotecan ) Treat Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Lurtotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Confirmed recurrent small cell lung cancer . One prior treatment chemotherapy . At least three week since last chemotherapy treatment recovery related side effect . At least three week since last chest radiotherapy least 10 day since head irradiation recovery acute side effect . At least one target tumor less equal 20 mm ( less equal 10 mm spiral CTscan ) . If patient previous documented Central Nervous System ( CNS ) involvement , control disease acceptable . Superior vena cava syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>